Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Cash Flows

v3.5.0.2
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
9 Months Ended
Sep. 30, 2016
Sep. 30, 2015
Cash flows from operating activities:    
Net loss $ (11,423) $ (33,031)
Adjustments to reconcile net loss to net cash provided by operating activities:    
Depreciation and amortization 72,612 20,073
Non-cash interest 2,063 2,176
Amortization of deferred financing costs 175 1,175
Losses from investments in investees 5,147 6,067
Equity-based compensation – employees and non-employees 34,939 17,765
Revenue from receipt of equity 0 (140)
Realized loss (gain) on equity securities and disposal of fixed assets 943 (216)
Loss on conversion of 3.00% convertible senior notes 0 (943)
Change in fair value of derivative instruments 5,889 34,100
Change in fair value of contingent consideration 15,604 6,471
Gain on deconsolidation of SciVac 0 (17,340)
Deferred income tax benefit (30,982) (96,713)
Changes in assets and liabilities, net of the effects of acquisitions:    
Accounts receivable, net (28,974) (5,704)
Inventory, net (2,726) (5,724)
Other current assets and prepaid expenses (24,310) (4,225)
Other assets (402) 1,262
Accounts payable (16,141) (35,504)
Foreign currency measurement (433) 776
Deferred revenue (56,256) 246,262
Accrued expenses and other liabilities 36,015 36,788
Net cash provided by operating activities 1,740 173,375
Cash flows from investing activities:    
Investments in investees (9,171) (3,000)
Acquisition of businesses, net of cash 15,878 (78,862)
Purchase of marketable securities (15,631) 0
Maturities of short-term marketable securities 15,634 0
Proceeds from the sale of property, plant and equipment 1,082 0
Acquisition of intangible assets (5,000) (5,000)
Capital expenditures (17,015) (4,422)
Net cash used in investing activities (14,223) (91,284)
Cash flows from financing activities:    
Issuance of 2033 Senior Notes, net, including related parties 0 81
Proceeds from the exercise of Common Stock options and warrants 6,112 25,180
Cash from non-controlling interest 0 100
Borrowings on lines of credit 15,816 111,359
Repayments of lines of credit (58,901) (103,544)
Net cash (used in) provided by financing activities (36,973) 33,176
Effect of exchange rate changes on cash and cash equivalents 504 (30)
Net (decrease) increase in cash and cash equivalents (48,952) 115,237
Cash and cash equivalents at beginning of period 193,598 96,907
Cash and cash equivalents at end of period 144,646 212,144
SUPPLEMENTAL INFORMATION:    
Interest paid 2,519 2,917
Income taxes paid, net 8,045 1,383
Shares issued upon the conversion of:    
Common Stock options and warrants, surrendered in net exercise 350 14,241
2033 Senior Notes    
Shares issued upon the conversion of:    
2033 Senior Notes 0 120,299
Transition Therapeutics    
Issuance of capital stock to acquire or contingent consideration settlement:    
Capital stock issued 58,530 0
Bio-Reference Laboratories, Inc.    
Issuance of capital stock to acquire or contingent consideration settlement:    
Capital stock issued 0 950,010
EirGen Pharma Limited    
Issuance of capital stock to acquire or contingent consideration settlement:    
Capital stock issued 0 33,569
OPKO Health Europe    
Issuance of capital stock to acquire or contingent consideration settlement:    
Capital stock issued 313 1,813
OPKO Renal    
Issuance of capital stock to acquire or contingent consideration settlement:    
Capital stock issued 25,986 20,113
Xenetic Biosciences, Inc.    
Issuance of capital stock to acquire or contingent consideration settlement:    
Capital stock issued $ 4,856 $ 0